Day: May 13, 2021

Viralytics band gets back together for ImmVirX cancer start-up

Join Our Mailing List

Our mission is to develop receptor targeted, oncolytic RNA immunotherapies to provide durable responses and high quality of life in patients with some of the most globally prevalent cancers

About Us

Our Technology

A clinical stage company developing receptor targeted oncolytic RNA immunotherapies to enable powerful and durable responses in the most globally prevalent cancers with high unmet need.

Twitter Linkedin

Company

About
Leadership Team
- Board
- Management Team
Our Technology
Clinical
Investor Centre
Recruitment
Contact

About
Leadership Team
- Board
- Management Team
Our Technology
Clinical
Investor Centre
Recruitment
Contact

Viralytics band gets back together for ImmVirX cancer start-up

Join Our Mailing List

Our mission is to develop receptor targeted, oncolytic RNA immunotherapies to provide durable responses and high quality of life in patients with some of the most globally prevalent cancers

Company

© 2024 ImmVirX Pty Ltd • Site by Noise